{"created":"2024-11-19T08:11:49.700560+00:00","id":2000651,"links":{},"metadata":{"_buckets":{"deposit":"e87dabc2-408d-4606-aab8-d3a9e1f5bf37"},"_deposit":{"created_by":11,"id":"2000651","owner":"11","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"2000651"},"status":"published"},"_oai":{"id":"oai:hirosaki.repo.nii.ac.jp:02000651","sets":["557:561:1731912205403"]},"author_link":[],"control_number":"2000651","item_3_biblio_info_8":{"attribute_name":"bibliographic_information","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2024-10-30","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"30","bibliographicPageStart":"22","bibliographicVolumeNumber":"75","bibliographic_titles":[{"bibliographic_title":"弘前医学","bibliographic_titleLang":"ja"},{"bibliographic_title":"Hirosaki Medical Journal","bibliographic_titleLang":"en"}]}]},"item_3_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"PURPOSE: Anamorelin, a ghrelin receptor agonist, is approved in Japan for the treatment of cachexia in patients with lung and gastrointestinal cancer. However, there is limited research on the usefulness of  anamorelin in clinical settings.\nMETHODS: A total of 40 patients with non-small cell lung cancer and cachexia who were prescribed  anamorelin between July 2021 and November 2022, were  retrospectively assessed. A logistic regression analysis was used to analyze the association between background characteristics and early discontinuation of  treatment with anamorelin （within 4 weeks）.\nRESULTS: The median age was 67 years （range, 36-88）, and 65% of the patients were male. The early discontinuation group included 11 patients （27.5%）. An Eastern Cooperative Oncology Group Performance Status （ECOG-PS） score ≥2 （odds ratio, 7.85; 95% confidence interval, 1.43-43.21; P=0.018） was associated with early discontinuation. A total of 18/40 patients were able to continue anamorelin treatment for 12 weeks, and the mean change in body weight was +2.31 kg, which was a significant change from the weight recorded at baseline（ P=0.027）.\nCONCLUSION: This study indicates that anamorelin is unlikely to be useful for patients with a poor general condition（ ECOG-PS score ≥2）.","subitem_description_language":"en","subitem_description_type":"Abstract"}]},"item_3_publisher_35":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"弘前大学大学院医学研究科","subitem_publisher_language":"ja"}]},"item_3_source_id_11":{"attribute_name":"item_3_source_id_11","attribute_value_mlt":[{"subitem_source_identifier":"AN00211444","subitem_source_identifier_type":"NCID"}]},"item_3_source_id_9":{"attribute_name":"item_3_source_id_9","attribute_value_mlt":[{"subitem_source_identifier":"2434-4656","subitem_source_identifier_type":"EISSN"}]},"item_3_text_4":{"attribute_name":"著者所属","attribute_value_mlt":[{"subitem_text_language":"en","subitem_text_value":"Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine"}]},"item_3_version_type_18":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yoshiko, Ishioka","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Hisashi, Tanaka","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Tomonori, Makiguchi","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Hiroaki, Sakamoto","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Toshihiro, Shiratori","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Kageaki, Taima","creatorNameLang":"en"}]},{"creatorNames":[{"creatorName":"Sadatomo, Tasaka","creatorNameLang":"en"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2024-11-19"}],"filename":"Hirosaki Med J 75-1_22.pdf","filesize":[{"value":"275 KB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"objectType":"fulltext","url":"https://hirosaki.repo.nii.ac.jp/record/2000651/files/Hirosaki Med J 75-1_22.pdf"},"version_id":"a7940064-3eb7-41c1-b9ba-7868e1806e7c"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"anamorelin","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"cachexia","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"NSCLC","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"item_resource_type","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Factors associated with the effect of anamorelin on cachexia in patients with non-small cell lung cancer","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Factors associated with the effect of anamorelin on cachexia in patients with non-small cell lung cancer","subitem_title_language":"en"}]},"item_type_id":"3","owner":"11","path":["1731912205403"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2024-11-19"},"publish_date":"2024-11-19","publish_status":"0","recid":"2000651","relation_version_is_last":true,"title":["Factors associated with the effect of anamorelin on cachexia in patients with non-small cell lung cancer"],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2024-11-29T01:46:24.677048+00:00"}